Home » Pharmaceutical Articles » Leaders In The Generation, Development And Commercialization Of Novel Antibody-Based Biopharmaceutical Products
Leaders In The Generation, Development And Commercialization Of Novel Antibody-Based Biopharmaceutical Products
Antibody discovery companies generate revenues by out-licensing their core technologies and by in-licensing or acquiring proprietary product candidates
/24-7PressRelease.com/ -- Research and Markets (http://www.researchandmarkets.com/reports/c8291) has announced the addition of Therapeutic protein industry - value mapping to their offering
Many players in the pharmaceutical industry have announced that their long-term objective is to become a leader in the generation, development and commercialization of novel antibody-based biopharmaceutical products and to become fully integrated pharmaceutical companies. Although transgenic production represents a small portion of the current market, the impending shortage in traditional manufacturing capacity will likely compel pharmaceutical companies to reassess their long-term production strategies and provide a substantial near-term opportunity for transgenic-based companies to gain market penetration.
We have analyzed the key strategies of the industry in order to find the value drivers of the winners. The following findings will clarify the position of various top-tier industry players:
-Antibody discovery companies aim to build relatively large and diversified product portfolios, including a mix of out-licensed and internally developed product candidates, by utilizing several technologies.
-Target validation plays a key role in more than 25% of the large pharmaceutical genomic-related deals announced during the last two years.
-The speed and cost advantages of antibody discovery companies are gained through their core technologies (for example phage display technology) that will enable them to make cost-effective use of available human and capital resources.
-Antibody discovery companies generate revenues by out-licensing their core technologies and by in-licensing or acquiring proprietary product candidates.
-Scientific research studies are taking place to overcome the problem of protein delivery inside cells.
-Risk-reducing technologies are constantly being developed to overcome problems related to monoclonal antibody production.
Therapeutic protein industry - value mapping is a business intelligence analysis that contains background to commercialization of therapeutic proteins and their manufacturing. Is also includes profound analysis of profit gaining opportunities for transgenic manufacturers as well as analysis of therapeutic protein value chain. By reading the analysis you are able to identify solution needs that will have the greatest impact on bottom line efficiencies driving the value creation as well as understand investment characteristics, coupled with analysis of key trends and industry dynamics.
Report Contents:
1.Background to therapeutic proteins and their manufacturing
2.Key findings related to monoclonal antibody production and industry positions
3.Pharmaceutical value chain, profit gaining opportunity for Transgenic Manufacturers
Tables:
Table I. New biotech drug and vaccine approvals/new indication approvals by year
Table II. Monoclonal antibody based products in development
Table III. Biologics in development
Table IV. The value and revenue chain of an antibody or therapeutic protein
For more information visit http://www.researchandmarkets.com/reports/c8291
Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com |
|
|
Press Release Contact Information:
Patrick Good
Research and Markets
Press Officer
Voice: 00353 1 4151243
Fax: 00353 1 4100980
|
|
|
|
|
| PHARMACEUTICAL ARCHIVE SEARCH |
|
|
| |
| SUBMIT PHARMACEUTICAL NEWS |
|
|
| |
|
|
Advertise With Us |
About Us |
Contact Us